We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Biomarker for an Aggressive Breast Cancer Identified

By LabMedica International staff writers
Posted on 31 Aug 2014
Print article
Using bioinformatics, scientists have identified an overactive transcription factor strongly associated with basal-like breast carcinoma—providing a biomarker with potential for improved diagnostics and as a smart target for new therapeutics for patients with this highly aggressive, often chemotherapy-resistant cancer.

The biomarker STAT3 (signal transducer and activator of transcription 3) was identified by Northwestern University (Evanston, IL, USA) scientists Curt M. Horvath, professor of molecular biosciences and of microbiology-immunology, and Robert W. Tell, PhD, using breast cancer (BrCa) patient data from The Cancer Genome Atlas. Powerful computational and bioinformatics techniques were used to detect patterns of gene expression comparing two BrCa subtypes. They found a small number of genes that were activated by STAT3 signaling in basal-like BrCas but not in luminal BrCas. Data from 825 BrCa patients were analyzed, including protein expression, protein phosphorylation (generally indicating signal activation), and messenger RNA and microRNA expression data. Among various BrCas included in the basal-like cancer category is the highly aggressive form called triple negative cancer.

“We have teased out from large amounts of data that STAT3 activity correlates with distinct patterns of gene expression in one type of breast cancer but not in another,” said Prof. Horvath. The results suggest that a clinical study should be conducted of a STAT3-inhibiting drug. Currently there are no pills or injections targeting STAT3 for BrCa patients. This study “opens up the possibility that cancer subtype-specific signaling is driven by STAT3 and that STAT3 inhibitors may be more effective in patients diagnosed with basal-like cancers than in those with luminal cancers,” said Prof. Horvath.

Previous research has found the STAT3 protein to be overactive in many BrCas, but its role is not well understood. In addition to its known roles in cancerous cells, STAT3 in normal cells is an essential mediator of cytokine and growth factor signals important for diverse processes, including immunity and inflammation. Prof. Horvath and Dr. Tell identified 84 genes that are differentially expressed in basal-like cancer tumors compared to luminal cancer tumors. These genes are highly representative of immune response and inflammation processes consistent with the role of STAT3.

This is the first reported study to compare BrCa subtypes and gene expression patterns associated with STAT3 in the tumors of human patients. “The Cancer Genome Atlas is a really rich and growing database of publicly available data created to help us understand cancer,” said Prof. Horvath, “It allows basic scientists to ask interesting questions about cancer and contribute to clinical care.” He emphasized that this study is a statistical analysis and the findings need to be verified with careful laboratory and clinical experiments. He plans to conduct such a study with colleagues at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.

The findings were published August 19, 2014, in the online early edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

Northwestern University
The Cancer Genome Atlas


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.